Kereos
HCID Member | Biotech Specialty Pharma
4041 Forest Park Ave.
St. Louis, MO 63108 USA
phone: 314.633.1879
fax: 314.633.1878
Symbol Private
Founded 0
Employees
www.kereos.com
Research Sector Biotech Specialty Pharma
Summary Description
Therapeutic delivery systems and imaging agents for the identification and treatment of cancer and cardiovascular disease
Management
Robert A. Beardsley, Ph.D., President and Chief Executive Officer; Catherine L. Matthes, Chief Financial Officer; Phillip M. Buckler, Vice President of Regulatory Affairs and Quality; Allen Nickols, Ph.D., Vice President of Biology; Dennis P. Riley, Ph.D., Senior Vice President of Research & Development
Keywords
molecular imaging agents, cancer, cardiovascular disease, oncology, cardiovascular, imaging

Comment | Printable Version | Jun. 27, 2008
If you work for Kereos and want to update this profile, click here

Description
Kereos produces molecular imaging agents with improved specificity and unique capabilities that enable the earlier and more definitive diagnosis of cancer and cardiovascular disease. Furthermore, Kereos' targeted therapeutics recognize definitive disease biomarkers to precisely deliver powerful payloads of proven chemotherapeutics, thereby making them potentially more effective and less toxic in the treatment of disease.
Products / Services
Kereos' product pipeline includes: the KI-0001, an MRI agent used for the detection of tumors, which enables their identification practically back to the point where they first become tumors; the KI-002, an MRI agent used for the detection of cardiovascular disease that can identify those at high risk and therefore lead to more effective treatments and improved prognoses; and the KI-100x, a targeted chemotherapeutic for solid tumors, which has been shown to significantly inhibit tumor growth in preliminary studies.
Technology / Differentiation
Kereos' product development addresses two major necessities associated with the diagnosis and treatment of cancer and cardiovascular disease, namely the capability for early detection and the targeted distribution of therapeutic agents to minimize toxicity and side effects. Its proprietary agents in these realms uniquely facilitate the diagnosis and treatment of these diseases.
Market / Customers
In the U.S., more than 1.7 million people are diagnosed with cancer annually. More than $60 billion is spent on treatment.
Status
With lead candidates projected to enter the clinic, Kereos is at the forefront in bringing targeted therapy and molecular imaging to patients, independently and with its partners. In September 2006, the company announced the publication of a preclinical study in "Arteriosclerosis, Thrombosis, and Vascular Biology" demonstrating the ability of Kereos' technology to detect and treat atherosclerotic plaques.


2008-11-22-1853